Abstract
The BACE1 enzyme is a key target for Alzheimer's disease. During our BACE1 research efforts, fragment screening revealed that bicyclic thiazine 3 had low millimolar activity against BACE1. Analysis of the co-crystal structure of 3 suggested that potency could be increased through extension toward the S3 pocket and through conformational constraint of the thiazine core. Pursuit of S3-binding groups produced low micromolar inhibitor 6, which informed the S3-design for constrained analogs 7 and 8, themselves prepared via independent, multi-step synthetic routes. Biological characterization of BACE inhibitors 6-8 is described.
Keywords:
BACE inhibitor; Complex organic synthesis; Conformational constraint; Stereoselective; Structure-based drug design.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Amyloid Precursor Protein Secretases / antagonists & inhibitors*
-
Amyloid Precursor Protein Secretases / chemistry
-
Amyloid Precursor Protein Secretases / isolation & purification
-
Animals
-
Aspartic Acid Endopeptidases / antagonists & inhibitors*
-
Aspartic Acid Endopeptidases / chemistry
-
Aspartic Acid Endopeptidases / isolation & purification
-
Brain Chemistry
-
Bridged Bicyclo Compounds / chemical synthesis*
-
Bridged Bicyclo Compounds / chemistry
-
Crystallography, X-Ray
-
Drug Design
-
Humans
-
Mice
-
Molecular Conformation
-
Molecular Docking Simulation
-
Protease Inhibitors / chemical synthesis*
-
Protease Inhibitors / chemistry
-
Stereoisomerism
-
Thiazines / chemical synthesis*
-
Thiazines / chemistry
Substances
-
Bridged Bicyclo Compounds
-
Protease Inhibitors
-
Thiazines
-
Amyloid Precursor Protein Secretases
-
Aspartic Acid Endopeptidases
-
BACE1 protein, human